ijms-logo

Journal Browser

Journal Browser

Special Issue "Cardiovascular Diseases–A Focus on Atherosclerosis, Its Prophylaxis, Complications and Recent Advancements in Therapies"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: 31 July 2021.

Special Issue Editor

Dr. Łukasz Bułdak
E-Mail
Guest Editor
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
Interests: atherosclerosis; hyperlipidemia; diabetes; arterial hypertension; obesity; clinical pharmacology; endocrinology

Special Issue Information

Dear Colleagues,

Despite tremendous advancements in the treatment of cardiovascular diseases and the advent of several new groups of drugs, the burden of morbidity and mortality resulting from atherosclerotic complications is still high. Atherosclerotic plaques are thought to be the essence of the disease, but in fact they are the mere final stage of numerous pathophysiologic processes involved in atherogenesis. These include hyperlipidaemia, diabetes, arterial hypertension, obesity, and many others. All these conditions are associated with an improper lifestyle and with extensive low-level inflammatory state and oxidative stress. The containment strategies recently introduced to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic  have resulted in reduced physical activity and the worsening of the dietary habits.

 Therefore, it is imperative to refocus on the importance of therapeutic lifestyle changes and propose novel preventive measures to counteract the consequences of the current and potentially future pandemic restrictions. Many drugs that are successfully used in the therapy of specific conditions have shown additional pleiotropic effects that are partly explained by their impact on cytokine signaling, their antioxidant capabilities, and their effects on micro-RNAs. Nevertheless, new therapies based on other mechanisms are needed. It also should be stressed that significant improvements have been achieved in the field of angioplasty, with novel stents and devices to improve the cardiac function, which is important to deal with the complications of atherosclerosis.

For this Special Issue, we urge authors to share their recent work on the epidemiology, prevention, and treatment of cardiovascular diseases, especially in the context of the coronavirus pandemic.

Dr. Łukasz Bułdak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherosclerosis
  • cardiovascular disease
  • oxidative stress
  • inflammation
  • coronavirus

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
Int. J. Mol. Sci. 2021, 22(9), 4420; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22094420 - 23 Apr 2021
Viewed by 279
Abstract
Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption [...] Read more.
Cardiovascular diseases (CVDs) have been classified into several types of disease, of which atherosclerosis is the most prevalent. Atherosclerosis is characterized as an inflammatory chronic disease which is caused by the formation of lesions in the arterial wall. Subsequently, lesion progression and disruption ultimately lead to heart disease and stroke. The development of atherosclerosis is the underlying cause of approximately 50% of all deaths in westernized societies. Countless studies have aimed to improve therapeutic approaches for atherosclerosis treatment; however, it remains high on the global list of challenges toward healthy and long lives. Some patients with familial hypercholesterolemia could not get intended LDL-C goals even with high doses of traditional therapies such as statins, with many of them being unable to tolerate statins because of the harsh side effects. Furthermore, even in patients achieving target LDL-C levels, the residual risk of traditional therapies is still significant thus highlighting the necessity of ongoing research for more effective therapeutic approaches with minimal side effects. Decoy-based drug candidates represent an opportunity to inhibit regulatory pathways that promote atherosclerosis. In this review, the potential roles of decoys in the treatment of atherosclerosis were described based on the in vitro and in vivo findings. Full article
Show Figures

Figure 1

Open AccessReview
Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis
Int. J. Mol. Sci. 2021, 22(4), 1659; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22041659 - 07 Feb 2021
Viewed by 980
Abstract
The current pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While this respiratory virus only causes mild symptoms in younger healthy individuals, elderly people and those with cardiovascular diseases such as systemic hypertension are susceptible [...] Read more.
The current pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While this respiratory virus only causes mild symptoms in younger healthy individuals, elderly people and those with cardiovascular diseases such as systemic hypertension are susceptible to developing severe conditions that can be fatal. SARS-CoV-2 infection is also associated with an increased incidence of cardiovascular diseases such as myocardial injury, acute coronary syndrome, and thromboembolism. Understanding the mechanisms of the effects of this virus on the cardiovascular system should thus help develop therapeutic strategies to reduce the mortality and morbidity associated with SARS-CoV-2 infection. Since this virus causes severe and fatal conditions in older individuals with cardiovascular comorbidities, effective therapies targeting specific populations will likely contribute to ending this pandemic. In this review article, the effects of various viruses—including other coronaviruses, influenza, dengue, and human immunodeficiency virus—on the cardiovascular system are described to help provide molecular mechanisms of pathologies associated with SARS-CoV-2 infection and COVID-19. The goal is to provide mechanistic information from the biology of other viral infections in relation to cardiovascular pathologies for the purpose of developing improved vaccines and therapeutic agents effective in preventing and/or treating the acute and long-term consequences of SARS-CoV-2 and COVID-19. Full article
Show Figures

Figure 1

Back to TopTop